Blue Cross Blue Shield OK iron testing Coverage Update

Coverage Criteria for Iron-Related Laboratory Tests

inv-01: Ferritin measurement — covered indications

Measurements may be reimbursable in the following specific clinical contexts:

Ferritin reimbursable indications: Serum ferritin measurement may be reimbursable for: a) evaluation of an individual with abnormal hemoglobin and/or hematocrit levels; b) evaluation and monitoring of iron overload disorders; c) individuals with symptoms of hemochromatosis (see Note 1: joint pain, fatigue, unexplained weight loss, abnormal bronze or gray skin color, abdominal pain, loss of sex drive); d) individuals with first-degree relatives (parents, full siblings, children) with confirmed hereditary hemochromatosis (HH); e) evaluation of individuals with liver disease; f) evaluation of hemophagocytic lymphohistiocytosis (HLH) and Still Disease; g) in males with secondary hypogonadism; h) monitoring at a frequency of every 1 to 3 months for: i) patients with chronic kidney disease receiving or being considered for anemia treatment, and ii) individuals on iron therapy.

Enumerated as alternate reimbursable indications

inv-02: Transferrin / transferrin saturation — covered indications

Transferrin/transferrin saturation (via serum iron and TIBC) reimbursable when any of the following apply:

Transferrin/transferrin saturation reimbursable indications: Transferrin/transferrin saturation measurement (calculated using serum iron and iron binding capacity/TIBC) may be reimbursable for: a) evaluation of iron overload in individuals with symptoms of hemochromatosis; b) evaluation of iron overload in individuals with first-degree relatives with confirmed hereditary hemochromatosis (HH); c) evaluation of iron deficiency anemia.

Listed as alternate indications

inv-03: Not reimbursable / screening — explicit non-covered uses and screening exclusions

Explicit non-covered or not reimbursable items:

Non-reimbursable tests/uses: In asymptomatic individuals, use of ferritin or transferrin (including transferrin saturation) as a screening test is not reimbursable; serum hepcidin testing (including immunoassays) is not reimbursable; use of GlycA testing to measure or monitor transferrin or other glycosylated proteins is not reimbursable.

These are explicit negative coverage statements

This policy does not address testing for carbohydrate-deficient transferrin; that analyte is explicitly out of scope for the coverage rules described here.

The provided document excerpts contain no additional explicit exclusion conditions beyond those called out in the main coverage text; providers should refer to full plan documents for any product‑specific exclusions not captured here.

The policy states that use of ferritin or transferrin measurements, including calculated transferrin saturation, as a screening test in asymptomatic individuals is not reimbursable and may be denied.

Within the provided chunks there are no additional explicit statements labeled as 'not medically necessary' beyond the screening and specific non‑reimbursable items already noted; for definitive determinations, review of the full policy text and plan documents is recommended.

Clinical Indications Considered Covered

inv-22: Evaluation of iron deficiency anemia, iron overload disorders, symptoms suggestive of hemochromatosis, first-degree relatives of confirmed HH, liver disease, HLH/Still Disease, and males with secondary hypogonadism.

Covered clinical evaluations: Measurement of serum ferritin and related iron studies for evaluation of: iron deficiency anemia; iron overload disorders; individuals with symptoms suggestive of hemochromatosis (see Note 1 for symptom examples); first-degree relatives of individuals with confirmed hereditary hemochromatosis (parents, full siblings, children); liver disease; hemophagocytic lymphohistiocytosis (HLH) and Still Disease; and males with secondary hypogonadism.

Policy cites NIDDK symptoms of hemochromatosis as context

inv-23: Assessment and management of iron deficiency, iron-deficiency anemia, and iron overload conditions (including hemochromatosis) as supported by cited literature.

Assessment and management of iron deficiency, iron-deficiency anemia, and iron overload conditions (including hemochromatosis) as supported by cited literature:

Literature-supported uses: Use of ferritin and transferrin/transferrin saturation testing for assessment and management of iron deficiency, iron-deficiency anemia, and iron overload (including hereditary hemochromatosis) is supported by cited clinical studies and guidelines (see references). Clinical context includes physiologically based ferritin thresholds, challenges of assessment in inflammation, and perioperative and chronic disease management considerations.

Tests and Uses Not Covered

The policy explicitly lists the following as not covered / not reimbursable: serum hepcidin testing (including immunoassays) and GlycA testing when used to measure or monitor transferrin or other glycosylated proteins. These tests may be denied if submitted for reimbursement.

The policy update history in the provided excerpts notes literature and reference revisions but does not enumerate additional tests or indications as not covered; no further not‑covered items are specified in these chunks.

Procedure and Billing Codes

Procedure Codes listedCPT

82728	Ferritin
83540	Iron; total (serum, plasma)
83550	TIBC (total iron-binding capacity) or UIBC
84466	Transferrin; total iron binding capacity (may map variably)
84999	Unlisted chemistry procedure
0024U	Hepcidin, blood, quantification by mass spectrometry (example U-code)
0251U	Hepcidin assay (example U-code)

Recommended Monitoring Frequency

Serum ferritin monitoring — frequency for CKD and iron therapy

PopulationPatients with chronic kidney disease receiving or being considered for anemia treatment; individuals on iron therapy

FrequencyEvery 1 to 3 months

PurposeEvaluation and monitoring of iron status during anemia treatment or while on iron therapy

FREQUENCY LIMITS — notes

Policy text availableNo additional explicit frequency limits beyond those stated in the policy excerpts were provided in the source chunks.

Action for providersFollow the specified frequency in the policy (see ferritin monitoring: every 1 to 3 months) and check plan documents for product-specific rules.

Provider Responsibilities and Actionable Alerts

Note

Product-specific coverage — check plan documents

Check plan documents for product-specific coverage — not all requirements apply to every product. If a conflict exists between this Clinical Payment and Coding Policy and a member's plan documents (e.g., Certificate of Benefits, summary plan description) the plan document governs; if a conflict exists with a provider contract, the provider contract governs.

Review Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents for product-specific rules and member eligibility.
BCBSOK may use reasonable discretion interpreting and applying this policy; plan documents and provider contracts take precedence where applicable.

Note

No explicit prior authorization requirements in this policy

No prior authorization or other explicit authorization requirements are specified in the provided policy excerpts. Providers should follow applicable plan documents and any separate prior authorization processes required by the member's product or network.

If a product requires prior authorization per its plan documents, follow that process — this policy does not replace product-specific authorization rules.

Ordering and Test Submission Requirements

Note

Check plan documents; no clinician-type ordering restriction specified

Review plan documents for product-specific requirements; the policy does not restrict who may order tests by clinician type in the provided excerpts.

Note

No specific ordering restrictions stated in excerpts

The provided policy excerpts do not specify special ordering restrictions or which clinicians may order the tests; consult the member’s plan documents for any product-specific ordering rules.

Background and Clinical Context

Serum ferritin and measures derived from serum iron and iron‑binding capacity (used to calculate transferrin saturation) are described as primary laboratory biomarkers for assessing iron status. Ferritin is used to evaluate both iron deficiency (for example, in the workup of abnormal hemoglobin/hematocrit or iron‑deficiency anemia) and iron overload (including monitoring in hemochromatosis and related disorders), while transferrin/transferrin saturation is reimbursable for evaluation of iron overload and iron deficiency anemia in the clinical contexts listed.

Definitions and Key Terms

First-degree relative — definition

DefinitionParents, full siblings, and children of the individual

ContextUsed to identify individuals at increased risk for hereditary hemochromatosis when a first-degree relative has confirmed HH.

Policy referenceSee Note 2 in reimbursement information for definition and implications for transferrin/ferritin testing.

Iron biomarkers — listed assays and role

Key biomarkersSerum ferritin, hepcidin, transferrin receptor (and related proteins)

Clinical roleAssess iron deficiency, iron-deficiency anemia, and iron overload conditions (including hemochromatosis).

Policy Revision History

2024-03-15literature_and_references_updatedLatest

Document updated with a literature review and references revised or added; reimbursement information unchanged.

2023-06-15literature_and_references_updated

Document updated with a literature review; reimbursement information revised for clarity and references revised (some added, others removed).

2022-11-01policy_created

OpenPayer

Diagnostic Testing of Iron Homeostasis and Metabolism

Coverage Criteria for Iron-Related Laboratory Tests

Clinical Indications Considered Covered

Tests and Uses Not Covered

Procedure and Billing Codes

Recommended Monitoring Frequency

Provider Responsibilities and Actionable Alerts

Ordering and Test Submission Requirements

Background and Clinical Context

Definitions and Key Terms

Policy Revision History